Boothbay Fund Management LLC Makes New Investment in CytomX Therapeutics, Inc. $CTMX

Boothbay Fund Management LLC bought a new position in CytomX Therapeutics, Inc. (NASDAQ:CTMX) in the third quarter, HoldingsChannel.com reports. The fund bought 1,237,057 shares of the biotechnology company’s stock, valued at approximately $3,946,000.

Other large investors also recently modified their holdings of the company. Farther Finance Advisors LLC bought a new stake in shares of CytomX Therapeutics during the third quarter valued at approximately $25,000. Bay Colony Advisory Group Inc d b a Bay Colony Advisors bought a new position in CytomX Therapeutics in the 3rd quarter worth approximately $34,000. Truist Financial Corp acquired a new position in CytomX Therapeutics during the 3rd quarter worth $40,000. Invesco Ltd. bought a new position in CytomX Therapeutics in the 2nd quarter valued at $32,000. Finally, Pursue Wealth Partners LLC bought a new position in CytomX Therapeutics in the 2nd quarter valued at $33,000. 67.77% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of equities research analysts have recently weighed in on CTMX shares. Guggenheim restated a “buy” rating and set a $10.00 target price on shares of CytomX Therapeutics in a research report on Monday, March 9th. JPMorgan Chase & Co. upgraded CytomX Therapeutics from a “neutral” rating to an “overweight” rating and raised their price target for the company from $7.00 to $12.00 in a report on Monday. Piper Sandler lifted their price objective on CytomX Therapeutics from $6.50 to $10.00 and gave the stock an “overweight” rating in a research report on Tuesday, January 20th. Cantor Fitzgerald boosted their price objective on CytomX Therapeutics from $6.00 to $10.00 and gave the stock an “overweight” rating in a report on Wednesday, February 4th. Finally, Oppenheimer restated an “outperform” rating and set a $12.00 target price on shares of CytomX Therapeutics in a research report on Monday. Eight equities research analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $10.88.

CytomX Therapeutics Stock Up 44.2%

Shares of NASDAQ CTMX opened at $6.75 on Tuesday. CytomX Therapeutics, Inc. has a twelve month low of $0.40 and a twelve month high of $8.21. The stock has a market cap of $1.14 billion, a price-to-earnings ratio of 16.88 and a beta of 2.44. The company’s fifty day moving average is $5.24 and its 200-day moving average is $4.07.

CytomX Therapeutics News Roundup

Here are the key news stories impacting CytomX Therapeutics this week:

• Positive Sentiment: Phase 1 expansion data show solid activity in late‑line colorectal cancer — confirmed response rates of 32% at 10 mg/kg Q3W and 20% at 8.6 mg/kg Q3W, estimated PFS ~7.1 months at the higher dose, and manageable safety with ongoing dose optimization. Management is targeting mid‑year FDA interactions to align on a potential registrational trial. Varsetatug Masetecan Continues to Demonstrate Positive Data
• Positive Sentiment: Analyst upgrades and higher price targets lifted sentiment — HC Wainwright raised its target to $17 (buy) and JPMorgan upgraded CTMX to overweight with a $12 target; Seeking Alpha and Benzinga published bullish takes tying valuation to Varseta‑M’s late‑line mCRC opportunity. These notes reinforced upside expectations. Mid‑Cap CytomX Therapeutics’ Colorectal Cancer Data Fuels Stock Rally
• Neutral Sentiment: Market reaction and high trading volume: CTMX experienced unusually heavy volume and a large pre‑market move as headlines circulated and investors digested the clinical readout plus analyst commentary. That amplifies intraday volatility but is informational rather than fundamental by itself. Why CTMX Stock Is Soaring Pre‑Market
• Negative Sentiment: Proposed $250M underwritten public offering of common stock and pre‑funded warrants — the financing will be dilutive and typically weighs on near‑term per‑share metrics despite extending the cash runway for development. CytomX Announces Proposed Public Offering
• Negative Sentiment: Q4 miss on EPS and revenue — CTMX reported a ($0.22) EPS vs. consensus (~$0.08 loss) and revenue well below estimates, reinforcing near‑term cash burn and highlighting the company remains pre‑commercial. These fundamentals contrast with the positive clinical news. CTMX Reports Q4 Loss, Misses Revenue Estimates

CytomX Therapeutics Company Profile

CytomX Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of next-generation therapeutics based on its proprietary Probody® platform. The company engineers masked antibody prodrugs that remain inactive in healthy tissue but are selectively activated in the tumor microenvironment. This approach is designed to enhance the safety and tolerability of antibody-based therapies, particularly those targeting immuno-oncology pathways.

At the core of CytomX’s pipeline is Pacmilimab (CX-072), an anti–PD-L1 Probody therapeutic currently undergoing clinical evaluation for multiple solid tumor indications.